Salud financiera de hoja de balance de Werewolf Therapeutics
Salud financiera controles de criterios 5/6
Werewolf Therapeutics tiene un patrimonio de los accionistas total de $89.4M y una deuda total de $25.6M, lo que sitúa su ratio deuda-patrimonio en 28.7%. Sus activos y pasivos totales son $140.0M y $50.7M respectivamente.
Información clave
28.7%
Ratio deuda-patrimonio
US$25.62m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$122.83m |
| Patrimonio | US$89.38m |
| Total pasivo | US$50.66m |
| Activos totales | US$140.04m |
Actualizaciones recientes sobre salud financiera
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($125.8M) de HOWL superan a sus pasivos a corto plazo ($12.5M).
Pasivo a largo plazo: Los activos a corto plazo de HOWL ($125.8M) superan a sus pasivos a largo plazo ($38.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: HOWL tiene más efectivo que su deuda total.
Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de HOWL se ha reducido en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: HOWL tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: HOWL dispone de suficiente cash runway para 2.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 15.7% cada año.